← 產業報告目錄
Antibody Conjugate Oligonucleotide Market Size, Share & Trends Analysis Report By Type (Monoclonal Antibody-Oligonucleotide Conjugates, Polyclonal Antibody-Oligonucleotide Conjugates, Others), By Oligonucleotide Type (Antisense Oligonucleotides, Small Interfering RNA (siRNA), Others), By Target Disease (Oncology, Autoimmune Diseases, Neurological Disorders, Genetic Disorders, Others), By Region, And By Segment Forecasts, 2025-2034.
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-11頁數 180報告編號 INSIGHTACE-c181007d0b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide Antibody Conjugate Oligonucleotide Market is projected to register a CAGR of 10.3%.
The Antibody Conjugate Oligonucleotide sector involves new drugs that combine the selectivity of antibody targeting with the gene-modulating capabilities of oligonucleotides. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is driven by mounting interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold substantial shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody Conjugate Oligonucleotide Market Snapshot
Chapter 4. Global Antibody Conjugate Oligonucleotide Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Antibody Conjugate Oligonucleotide Market Industry Trends
4.10. Global Antibody Conjugate Oligonucleotide Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Antibody Conjugate Oligonucleotide Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share By Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
5.2.1. Monoclonal Antibody-Oligonucleotide Conjugates
5.2.2. Polyclonal Antibody-Oligonucleotide Conjugates
5.2.3. Others
Chapter 6. Antibody Conjugate Oligonucleotide Market Segmentation 2: By Oligonucleotide Type, Estimates & Trend Analysis
6.1. Market Share By Oligonucleotide Type, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Oligonucleotide Type:
6.2.1. Antisense Oligonucleotides
6.2.2. Small Interfering RNA (siRNA)
6.2.3. Others
Chapter 7. Antibody Conjugate Oligonucleotide Market Segmentation 3: By Target Disease, Estimates & Trend Analysis
7.1. Market Share By Target Disease, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Disease:
7.2.1. Oncology
7.2.2. Autoimmune Diseases
7.2.3. Neurological Disorders
7.2.4. Genetic Disorders
7.2.5. Others
Chapter 8. Antibody Conjugate Oligonucleotide Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. Global Antibody Conjugate Oligonucleotide Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
8.2.3. North America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Oligonucleotide Type, 2021-2034
8.2.4. North America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Target Disease, 2021-2034
8.3. Europe
8.3.1. Europe Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
8.3.3. Europe Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Oligonucleotide Type, 2021-2034
8.3.4. Europe Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Target Disease, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
8.4.3. Asia Pacific Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Oligonucleotide Type, 2021-2034
8.4.4. Asia Pacific Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Target Disease, 2021-2034
8.5. Latin America
8.5.1. Latin America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
8.5.3. Latin America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Oligonucleotide Type, 2021-2034
8.5.4. Latin America Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Target Disease, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
8.6.3. Middle East & Africa Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Oligonucleotide Type, 2021-2034
8.6.4. Middle East & Africa Antibody Conjugate Oligonucleotide Market Revenue (US$ Million) Estimates and Forecasts By Target Disease, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. AstraZeneca
9.2.1.1. Business Overview
9.2.1.2. Key Product Type/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Avidity Biosciences
9.2.3. Dyne Therapeutics
9.2.4. Tallac Therapeutics
9.2.5. Other Companies
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們